Edition:
United States

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

5.36USD
18 Jun 2018
Change (% chg)

$0.01 (+0.19%)
Prev Close
$5.35
Open
$5.34
Day's High
$5.36
Day's Low
$5.30
Volume
8,585
Avg. Vol
249,133
52-wk High
$19.30
52-wk Low
$3.76

Latest Key Developments (Source: Significant Developments)

NewLink Genetics, Cantor Fitzgerald Enter Controlled Equity Offering Sales Agreement
Tuesday, 13 Mar 2018 06:18am EDT 

March 13 (Reuters) - NewLink Genetics Corp ::NEWLINK GENETICS SAYS ON MARCH 12, CO ENTERED CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.NEWLINK GENETICS - UNDER TERMS CO MAY OFFER, SELL THROUGH CANTOR, SHARES OF CO'S COMMON STOCK PAR VALUE $0.01PER SHARE UP TO $60.0 MILLION.  Full Article

NewLink Genetics Qtrly Loss Per Share $0.37
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - NewLink Genetics Corp ::NEWLINK GENETICS REPORTS FOURTH QUARTER, YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES UPDATE FOR INDOXIMOD PROGRAMS.NEWLINK GENETICS CORP - QTRLY TOTAL OPERATING REVENUES $10.1 MILLION VERSUS $12.7 MILLION.NEWLINK GENETICS CORP - QTRLY BASIC AND DILUTED LOSS PER SHARE $0.37.  Full Article

Newlink Genetics Outlines 2018 Business Priorities
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Newlink Genetics Corp ::NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS.NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS.NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS.NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018.NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018.  Full Article

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Monday, 11 Dec 2017 05:35pm EST 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

NewLink Genetics reports Q3 loss per share $0.69
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - NewLink Genetics Corp :Q3 loss per share $0.69.NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​.NewLink Genetics Corp - Qtrly ‍total operating revenues $5.5 million versus $15.3 million.Q3 earnings per share view $-0.74, revenue view $3.4 million -- Thomson Reuters I/B/E/S.  Full Article

Newlink genetics announces FDA orphan-drug designation for Indoximod
Monday, 30 Oct 2017 09:00am EDT 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.  Full Article

Newlink Genetics prices public offering of common stock
Tuesday, 3 Oct 2017 08:53pm EDT 

Oct 3 (Reuters) - Newlink Genetics Corp :Newlink Genetics prices public offering of common stock.Newlink Genetics Corp - priced underwritten public offering of 5 million shares of its common stock at a price to public of $10.25 per share.  Full Article

NewLink Genetics announces proposed public offering of common stock
Tuesday, 3 Oct 2017 04:07pm EDT 

Oct 3 (Reuters) - Newlink Genetics Corp :NewLink Genetics announces proposed public offering of common stock.NewLink Genetics Corp - ‍intends to offer and sell up to $50 million of shares of its common stock in an underwritten public offering​.NewLink Genetics - ‍intends to use net proceeds from offering to fund research, development efforts to further advance its pipeline of product candidates​.  Full Article

NewLink Genetics forecasts co will have about $100 million in cash and cash equivalents on balance sheet
Monday, 25 Sep 2017 06:43am EDT 

Sept 25 (Reuters) - NewLink Genetics Corp :NewLink Genetics - forecasts that co will have about $100 million in cash and cash equivalents on its balance sheet as of December 31, 2017 - SEC filing.  Full Article

NewLink Genetics announces clinical collaboration with AstraZeneca​
Monday, 25 Sep 2017 06:00am EDT 

Sept 25 (Reuters) - NewLink Genetics Corp :Newlink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer.NewLink Genetics Corp - ‍Phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as study sponsor​.NewLink Genetics Corp - ‍announced that it has entered into a clinical collaboration agreement with AstraZeneca​.NewLink Genetics Corp - NewLink Genetics' share of aggregate expense of trial is not expected to have a material effect on its financial position​.NewLink Genetics Corp - ‍patients will also be enrolled into a smaller cohort evaluating combination of durvalumab with gemcitabine/abraxane​.  Full Article